Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Czerwinski, E.

Refine Results

Resource Type

Availability

Creation Date

Language

Search results

  • RSS Feed
(1 - 19 of 19)
Prevalence of FRAX risk factors and the osteoporosis treatment gap among women >= 70 years of age in routine primary care across 8 countries in Europe
The osteoporosis treatment gap in patients at risk of fracture in European primary care
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
EFFECT OF EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: FIVE-YEAR RESULTS FROM THE FREEDOM EXTENSION
Effects of up to 8 years of denosumab treatment in women with postmenopausal osteoporosis: Results: from the first 5 years of the FREEDOM extension
EIGHT YEARS OF DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST FIVE YEARS OF THE FREEDOM EXTENSION
The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
6 YEARS' DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: FIRST 3 YEARS OF THE FREEDOM EXTENSION
Denosumab treatment for 6 years in postmenopausal women with osteoporosis: The first 3 years of the freedom extension
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS FOR 6 YEARS: RESULTS FROM THE FIRST 3 YEARS OF THE FREEDOM EXTENSION
Six Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results From the First Three Years of the FREEDOM Extension
Extended Safety Observations From Denosumab Administration in Postmenopausal Women From the FREEDOM and FREEDOM Extension Trials
LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION
FIVE YEARS OF DENOSUMAB TREATMENT IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: PRELIMINARY RESULTS FROM THE FREEDOM EXTENSION STUDY
FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION
FREEDOM TRIAL FIRST-YEAR EXTENSION: RESULTS FROM 4 YEARS OF DENOSUMAB EXPOSURE IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS